Forest Laboratories Inc.

Chairman of the Board and Chief Executive Officer. Mr. Solomon has served as our Chief Executive Officer since 1977.

President and Chief Operating Officer since October 2006. President and Chief Executive Officer at Celsion Corporation from July 2005 to October 2006. For the ten years prior to July 2005, Dr. Olanoff served as Executive Vice President – Chief Science Officer at Forest.

Elaine Hochberg is our Senior Vice President – Marketing since December 1999 and Chief Commercial Officer since December 2007. Ms. Hochberg joined us in June 1997 as Vice President – Marketing of our wholly-owned subsidiary Forest Pharmaceuticals, Inc. In February 1998, she was promoted to Vice President – Marketing. Prior to joining us in 1997, Ms. Hochberg was Assistant Vice President – Marketing at Wyeth-Lederle Laboratories.

Francis I. Perier, Jr. is our Senior Vice President – Finance and Chief Financial Officer since September 2004. From March 2004 until joining us in September 2004, Mr. Perier was Vice President – Finance – Operations Planning – Americas Medicines at Bristol-Myers Squibb. For eight years prior to March 2004, Mr. Perier served in senior financial positions at Bristol-Myers Squibb including four years as Vice President – Finance, Planning, Business Development and Information Technology at its ConvaTec Division. Prior to that, Mr. Perier had been a partner at Deloitte & Touche, LLP.

Dan L. Goldwasser is an attorney in the New York office of Vedder Price, where he is a member of the firm's Corporate and Securities Practice. He is a graduate of Harvard University and Columbia Law School and has counseled dozens of companies (both private and public) in mergers, acquisitions, public offerings, private placements and tender offers. He is also an authority on restricted securities, representing both institutional and private investors in sales of restricted securities. Mr. Goldwasser is the author of A Guide to Rule 144 (PLI 1978), a treatise on restricted stock sales, as well as the chapter titled "The Underwritten Offering" in the treatise Securities Law Techniques published by Matthew Bender. More recently, he wrote the chapter on audit committees in Nonprofit Governance and Management (ABA 2002). He has also written numerous position papers and comment letters for the American Bar Association's Committee on Federal Regulation of Securities, on which he has served for over 35 years. Mr. Goldwasser has chaired and appeared in numerous symposia for the ABA, the Practising Law Institute and other bar associations on corporate and securities law topics, including programs on securities law opinions, blue sky laws, sales and resales of restricted securities, and directors and officers liability. He has also chaired an ABA satellite video program on business valuations. Mr. Goldwasser currently is a member of the American Bar Association's Committees on Federal Regulation of Securities and Law and Accounting, and he previously served on the Securities Law Committee of the Association of the Bar of the City of New York and the Committee on Corporation Law of the New York State Bar Association. He also serves on the board of directors of a public company and on its audit and compensation committees. In 2005, he was appointed as one of the five public members of the Auditing Standards Board, the senior technical committee of the AICPA with authority to publish statements of standards for the conduct of financial statement audits. The ASB statements are the authoritative standards for all non-public company audits.

President, The George Cohan Company, Inc., consultants, since June 1989.

Former President and Chief Operating Officer of Forest (December 1998 to September 2006). For eighteen years prior thereto, Mr. Goodman served as Vice President – Finance and Chief Financial Officer and in addition served as Executive Vice President – Operations since February 1998.

Clinical Professor and member of the Clinical Attending Staff Internal Medicine, Mount Sinai Medical School. Prior thereto Dr. Salans was Vice President – Research at Sandoz Pharmaceutical Corporation.

Associate Chief for Clinical Affairs, Division of Infectious Diseases, Massachusetts General Hospital (MGH). Dr. Basgoz previously served as Clinical Director, Infectious Diseases Division of MGH and serves as Associate Professor of Medicine, Harvard Medical School.